The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1386
ISSUE1386
March 19, 2012
Extended-Release Exenatide (Bydureon) for Type 2 Diabetes
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Extended-Release Exenatide (Bydureon) for Type 2 Diabetes
March 19, 2012 (Issue: 1386)
The FDA has approved a once-weekly extendedrelease
formulation of exenatide (Bydureon – Amylin),
an injectable glucagon-like peptide-1 (GLP-1) receptor
agonist, for treatment of type 2 diabetes.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.